data&donuts
  • Data & Donuts (thinky thoughts)
  • COLLABORATor
  • Data talks, people mumble
  • Cancer: The Brand
  • Time to make the donuts...
  • donuts (quick nibbles)
  • Tools for writers and soon-to-be writers
  • datamonger.health
  • The "How" of Data Fluency

CANCER: THE BRAND

Medicare cancer drug pricing "under the influence..."

7/28/2015

 
A group of more than 100 leading cancer experts are supporting a patient-based grassroots movement demanding action on the high price of cancer drugs--see petition at end of blog to participate.
Tefferi blames drug company greed, physicians who are too quick to prescribe new drugs without proven efficacy, health insurers willing to go along with upwards of $3,000-a-month co-pays, and a lack of federal government oversight adding checks and balances to a Wild West of drug pricing — especially for the federal health plan for seniors, Medicare, which is barred from negotiating drug prices. That prohibition was signed into law by President George W. Bush in 2003.

“The prices are fixed by the drug companies,” Tefferi said. “There is no regulation.”


Dataset for Pricing in the Market for Anticancer Drugs


chemodata20140825.csv
File Size: 12 kb
File Type: csv
Download File

Here is a dataset from "Pricing in the Market for Anticancer Drugs."Journal of Economic Perspectives: Vol. 29 No. 1 (Winter 2015). Download this guide to the dataset to help guide analyses.
Solutions needed now...
  • Create a post-FDA drug approval review mechanism to propose a fair price for new treatments, based on the value to patients and health care.
  • Allow Medicare to negotiate drug prices.
  • Allow the Patient-Centered Outcomes Research Institute, created through the Affordable Care Act initiatives to evaluate the benefits of new treatments, and similar organizations to include drug prices in their assessments of the treatment value.
  • Allow importation of cancer drugs across borders for personal use (e.g. prices in Canada are about half prices in the United States).
  • Pass legislation to prevent drug companies from delaying access to generic drugs.
  • Reform patent system to make it more difficult to prolong product exclusivity unnecessarily (patent “evergreening”).
  • Encourage organizations that represent cancer specialists and patients (American Society of Clinical Oncology, American Society of Hematology, American Association for Cancer Research, American Cancer Society, National Comprehensive Cancer Network) to consider the overall value of drugs and treatments in their guidelines.
How did this happen? Under the Influence CBS News
Picture
What can I do?
Click here --> Protest High Cancer Drug Prices so all Patients with Cancer have Access to Affordable Drugs to Save their Lives


Thoughtful discussions about content development and outcomes analytics that apply the principles and frameworks of health policy and economics to persistent and perplexing health and health care problems

Comments are closed.
    Bonny is a data enthusiast applying curated analysis and visualization to persistent tensions between health policy, economics, and clinical research in oncology.
    Follow @datamongerbonny

    Archives

    November 2020
    January 2020
    October 2019
    August 2019
    July 2019
    January 2019
    December 2018
    August 2018
    June 2018
    April 2018
    March 2018
    December 2017
    November 2017
    September 2017
    June 2017
    May 2017
    April 2017
    October 2016
    September 2016
    August 2016
    April 2016
    March 2016
    November 2015
    October 2015
    September 2015
    July 2015
    June 2015
    May 2015
    April 2015

    Categories

    All

    Subscribe to our mailing list

    * indicates required
    Email Format
Proudly powered by Weebly
  • Data & Donuts (thinky thoughts)
  • COLLABORATor
  • Data talks, people mumble
  • Cancer: The Brand
  • Time to make the donuts...
  • donuts (quick nibbles)
  • Tools for writers and soon-to-be writers
  • datamonger.health
  • The "How" of Data Fluency